Advertisement
ANSLY vs PDEX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANSLY is a Buy and PDEX is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANSLY’s FA Score shows that 1 FA rating(s) are green whilePDEX’s FA Score has 0 green FA rating(s).
- ANSLY’s FA Score: 1 green, 4 red.
- PDEX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANSLY’s TA Score shows that 5 TA indicator(s) are bullish while PDEX’s TA Score has 5 bullish TA indicator(s).
- ANSLY’s TA Score: 5 bullish, 3 bearish.
- PDEX’s TA Score: 5 bullish, 5 bearish.
Price Growth
ANSLY (@Pharmaceuticals: Other) experienced а 0.00% price change this week, while PDEX (@Pharmaceuticals: Other) price change was -1.08% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.86%. For the same industry, the average monthly price growth was -2.64%, and the average quarterly price growth was +7.09%.
Reported Earning Dates
PDEX is expected to report earnings on Oct 30, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (-0.86% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| ANSLY | PDEX | ANSLY / PDEX | |
| Capitalization | 3.03B | 111M | 2,732% |
| EBITDA | 260M | 14.1M | 1,844% |
| Gain YTD | 10.890 | -27.294 | -40% |
| P/E Ratio | 32.44 | 12.73 | 255% |
| Revenue | 2B | 66.6M | 3,008% |
| Total Cash | 88.5M | 7.16M | 1,236% |
| Total Debt | 806M | 16.6M | 4,855% |
ANSLY | PDEX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 87 | |
SMR RATING 1..100 | 91 | 36 | |
PRICE GROWTH RATING 1..100 | 44 | 65 | |
P/E GROWTH RATING 1..100 | 59 | 98 | |
SEASONALITY SCORE 1..100 | n/a | 36 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ANSLY's Valuation (18) in the null industry is somewhat better than the same rating for PDEX (65) in the Medical Or Nursing Services industry. This means that ANSLY’s stock grew somewhat faster than PDEX’s over the last 12 months.
PDEX's Profit vs Risk Rating (87) in the Medical Or Nursing Services industry is in the same range as ANSLY (100) in the null industry. This means that PDEX’s stock grew similarly to ANSLY’s over the last 12 months.
PDEX's SMR Rating (36) in the Medical Or Nursing Services industry is somewhat better than the same rating for ANSLY (91) in the null industry. This means that PDEX’s stock grew somewhat faster than ANSLY’s over the last 12 months.
ANSLY's Price Growth Rating (44) in the null industry is in the same range as PDEX (65) in the Medical Or Nursing Services industry. This means that ANSLY’s stock grew similarly to PDEX’s over the last 12 months.
ANSLY's P/E Growth Rating (59) in the null industry is somewhat better than the same rating for PDEX (98) in the Medical Or Nursing Services industry. This means that ANSLY’s stock grew somewhat faster than PDEX’s over the last 12 months.
| ANSLY | PDEX | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 57% | 4 days ago 89% |
| Stochastic ODDS (%) | 4 days ago 48% | 4 days ago 82% |
| Momentum ODDS (%) | N/A | 4 days ago 75% |
| MACD ODDS (%) | 4 days ago 53% | 4 days ago 74% |
| TrendWeek ODDS (%) | 4 days ago 37% | 4 days ago 74% |
| TrendMonth ODDS (%) | 4 days ago 38% | 4 days ago 73% |
| Advances ODDS (%) | 22 days ago 38% | N/A |
| Declines ODDS (%) | N/A | 7 days ago 73% |
| BollingerBands ODDS (%) | N/A | 4 days ago 74% |
| Aroon ODDS (%) | 4 days ago 44% | 4 days ago 60% |
Advertisement
ANSLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANSLY has been loosely correlated with BRSYF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ANSLY jumps, then BRSYF could also see price increases.
| Ticker / NAME | Correlation To ANSLY | 1D Price Change % | ||
|---|---|---|---|---|
| ANSLY | 100% | N/A | ||
| BRSYF - ANSLY | 61% Loosely correlated | N/A | ||
| IOBCF - ANSLY | 43% Loosely correlated | N/A | ||
| VERO - ANSLY | 33% Poorly correlated | -0.43% | ||
| FSPKF - ANSLY | 26% Poorly correlated | N/A | ||
| PDEX - ANSLY | 22% Poorly correlated | +1.01% | ||
More | ||||